Weight Loss Drugs Linked to Increased Facial Wrinkles and Volume Loss

The advent of GLP-1 receptor agonists (GLP-1 RAs), such as semaglutide and tirzepatide, has revolutionized the treatment of obesity and type 2 diabetes, offering significant health benefits through substantial weight reduction. While the systemic health advantages are well-documented, rapid and significant weight loss can sometimes lead to undesirable aesthetic changes, particularly affecting facial appearance. This study investigated the specific impact of pharmacologically induced weight loss on facial aesthetics, focusing on the prevalence and severity of wrinkles and volume loss.

The study revealed a significant increase in facial aging signs among patients using GLP-1 RAs compared to the control group. Patients on GLP-1 RAs showed a 35% higher incidence of new or worsened facial wrinkles and a 2.1-fold increase in perceived facial volume loss compared to the diet/exercise group. Specifically, 68% of the GLP-1 RA group experienced moderate to severe periorbital (around the eyes) and perioral (around the mouth) wrinkling, versus 33% in the control group (p<0.001). Furthermore, 43% of GLP-1 RA users reported dissatisfaction with their facial appearance post-weight loss, compared to 15% in the control group (p<0.005). The average facial aging score increased by 1.8 points in the GLP-1 RA group, while the control group saw an increase of 0.7 points (p<0.001), indicating a more pronounced aging effect with drug-induced weight loss.